Merck, Sharp & Dohme (MSD; NYSE: MRK) has announced an unfavorable outcome for a Phase III trial combining Keytruda (pembrolizumab) and Lynparza (olaparib) in the first-line treatment of metastatic non-squamous non-small cell lung cancer (NSCLC). The study, which aimed to evaluate the efficacy of this combination therapy, was halted after it did not achieve its primary endpoints of overall survival (OS) and progression-free survival (PFS).
MSD has indicated that it is in the process of thoroughly reviewing the data from the trial. The company has also confirmed that no new safety concerns were identified for the combined use of Keytruda and Lynparza, a finding that may be crucial for future studies and potential applications of this treatment approach.- Flcube.com
